Patient characteristics
| . | All (n = 314) . | Low suPAR ≤ 3.69 ng/mL (n = 157) . | High suPAR > 3.69 ng/mL (n = 157) . | Low vs high P . |
|---|---|---|---|---|
| Clinical data | ||||
| Median follow-up time (mo) | 38 | 48 | 23 | < .00011-155 |
| (range) | (0.3-57) | (2.5-55) | (0.3-57) | |
| AIDS-caused death | 167 | 64 | 103 | < .00011-154 |
| Drug at enrollment* | 161 | 76 | 85 | .31-154 |
| Gender (M/F) | 280/34 | 141/16 | 139/18 | .71-154 |
| Median age (y) | 39 | 37 | 41 | .0071-154 |
| (range) | (16-66) | (20-60) | (16-66) | |
| Route of infection | ||||
| Homosexual contact | 241 | 123 | 118 | .71-154 |
| Heterosexual contact | 46 | 24 | 22 | .51-154 |
| Other† | 27 | 10 | 17 | .21-154 |
| Serologic variables | ||||
| Median CD4 count (cells/mm3) | 204 | 264 | 130 | |
| (range) | (0-1116) | (1-992) | (0-1116) | < .00011-155 |
| n = 3051-153 | n = 154 | n = 151 | ||
| Median viral load‡ | 5.02 | 4.78 | 5.20 | |
| (range) | (2.30-6.86) | (2.30-6.72) | (2.30-6.86) | .0021-155 |
| n = 2501-153 | n = 125 | n = 125 | ||
| Median β2-microglobulin (nmol/L) | 218 | 200 | 248 | |
| (range) | (0-1802) | (0-530) | (0-1802) | < .00011-155 |
| n = 2951-153 | n = 150 | n = 145 | ||
| Median suPAR (ng/mL) | 3.69 | 3.03 | 4.46 | |
| (range) | (1.15-15.60) | (1.15-3.69) | (3.70-15.60) | NA |
| . | All (n = 314) . | Low suPAR ≤ 3.69 ng/mL (n = 157) . | High suPAR > 3.69 ng/mL (n = 157) . | Low vs high P . |
|---|---|---|---|---|
| Clinical data | ||||
| Median follow-up time (mo) | 38 | 48 | 23 | < .00011-155 |
| (range) | (0.3-57) | (2.5-55) | (0.3-57) | |
| AIDS-caused death | 167 | 64 | 103 | < .00011-154 |
| Drug at enrollment* | 161 | 76 | 85 | .31-154 |
| Gender (M/F) | 280/34 | 141/16 | 139/18 | .71-154 |
| Median age (y) | 39 | 37 | 41 | .0071-154 |
| (range) | (16-66) | (20-60) | (16-66) | |
| Route of infection | ||||
| Homosexual contact | 241 | 123 | 118 | .71-154 |
| Heterosexual contact | 46 | 24 | 22 | .51-154 |
| Other† | 27 | 10 | 17 | .21-154 |
| Serologic variables | ||||
| Median CD4 count (cells/mm3) | 204 | 264 | 130 | |
| (range) | (0-1116) | (1-992) | (0-1116) | < .00011-155 |
| n = 3051-153 | n = 154 | n = 151 | ||
| Median viral load‡ | 5.02 | 4.78 | 5.20 | |
| (range) | (2.30-6.86) | (2.30-6.72) | (2.30-6.86) | .0021-155 |
| n = 2501-153 | n = 125 | n = 125 | ||
| Median β2-microglobulin (nmol/L) | 218 | 200 | 248 | |
| (range) | (0-1802) | (0-530) | (0-1802) | < .00011-155 |
| n = 2951-153 | n = 150 | n = 145 | ||
| Median suPAR (ng/mL) | 3.69 | 3.03 | 4.46 | |
| (range) | (1.15-15.60) | (1.15-3.69) | (3.70-15.60) | NA |
NA indicates not applicable.
Patients receiving antiretroviral drug treatment at the time of enrollment.
Six patients were infected by intravenous drug use, 7 were infected by contaminated blood transfusions, 6 were hemophilia patients, and 8 had unknown route of infection.
log10 HIV-1 RNA molecules/mL plasma.
Nine patients with missing data for CD4 count, 64 patients with missing data for viral load, and 19 patients with missing data for β2-microglobulin.
Mann-Whitney test.
χ2 test.